ACell
General Information | |
Business: |
We are a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. Our products utilize our proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body’s ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. |
Industry: | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Employees: | 400 |
Founded: | 1999 |
Contact Information | |
Address | 6640 Eli Whitney Drive Columbia, MD 21046, US |
Phone Number | (800) 826-2926 |
Web Address | http://www.acell.com |
View Prospectus: | ACell |
Financial Information | |
Market Cap | $344.6mil |
Revenues | $100.3 mil (last 12 months) |
Net Income | $-1.3 mil (last 12 months) |
IPO Profile | |
Symbol | ACLL |
Exchange | NASDAQ |
Shares (millions): | 5.0 |
Price range | $14.00 - $16.00 |
Est. $ Volume | $75.0 mil |
Manager / Joint Managers | UBS Investment Bank/ Barclays/ RBC Capital Markets |
CO-Managers | SunTrust Robinson Humphrey |
Expected To Trade: | 7/20/2020 |
Status: | Withdrawn |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |